Out of these, the GRPR and the NPY(Y1)R are of particular interest for the development of radiolabeled heterobivalent peptidic agents as they are overexpressed in ≈75% [52] and 66–85% [53] of all breast cancer lesions, respectively, but only to an insignificant amount on healthy breast tissue. Here, GRPR is linked to breast carcinoma.